Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
AssigneePrecision Biologics, Inc.
InventorsJ. Andrew Bristol, Judith A. Kantor
Life of this patent
Estimating the term…
Abstract
The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
Claims14
A method for detecting the presence of cancer cells that express the 16C3 human colorectal and pancreatic carcinoma-associated antigen (CPAA) in a subject comprising
- (a) administering to said subject a labeled monoclonal antibody or fragment thereof, that binds the 16C3 CPAA and
- (b) detecting the presence of human carcinoma-associated protein antigen specifically bound by said antibody,
- wherein the presence of said human carcinoma-associated protein antigen is indicative of carcinoma cells that express the 16C3 CPAA;
- and
- wherein said antibody comprises a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 4, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3 or SEQ ID NO:
- 6;
- and said antibody comprises a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 7, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 8 or SEQ ID NO:
- 10 and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 9 or SEQ ID NO:
- 11.
A method for detecting a carcinoma expressing the 16C3 colorectal and pancreatic carcinoma-associated antigen (CPAA) comprising
- (a) contacting a test sample with a monoclonal antibody or fragment thereof, that binds the 16C3 CPAA and
- (b) assaying the expression of the 16C3 CPAA specifically bound by said antibody,
- wherein the presence of said 16C3 CPAA is indicative of a carcinoma
- wherein said antibody comprises a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 4, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3 or SEQ ID NO:
- 6;
- and said antibody comprises a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 7, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 8 or SEQ ID NO:
- 10, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 9 or SEQ ID NO:
- 11.
A method for detecting the presence of cancer cells that express the 16C3 human colorectal and pancreatic carcinoma-associated antigen (CPAA) in a subject comprising
- (a) administering to said subject a labeled monoclonal antibody or fragment thereof, that binds the 16C3 CPAA and
- (b) detecting the presence of human carcinoma-associated protein antigen specifically bound by said antibody,
- wherein the presence of said human carcinoma-associated protein antigen is indicative of carcinoma cells that express the 16C3 CPAA;
- and
- wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:
- 14, 16, 17, 18, 19, 20, 21, or 29;
- and said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 15, 22, 23, 24, 25, 26, 27, or 28.
A method for detecting a carcinoma expressing the 16C3 colorectal and pancreatic carcinoma-associated antigen (CPAA) comprising
- (a) contacting a test sample with a monoclonal antibody or fragment thereof, that binds the 16C3 CPAA and
- (b) assaying the expression of the 16C3 CPAA specifically bound by said antibody,
- wherein the presence of said 16C3 CPAA is indicative of a carcinoma
- wherein the presence of said human carcinoma-associated protein antigen is indicative of carcinoma cells that express the 16C3 CPAA;
- and
- wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:
- 14, 16, 17, 18, 19, 20, 21, or 29;
- and said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 15, 22, 23, 24, 25, 26, 27, or 28.
Dependencies are inferred from the claim text.